Nephrosant Revenue and Competitors
Estimated Revenue & Valuation
- Nephrosant's estimated annual revenue is currently $1M per year.
- Nephrosant's estimated revenue per employee is $77,500
- Nephrosant's total funding is $16M.
Employee Data
- Nephrosant has 13 Employees.
- Nephrosant grew their employee count by -62% last year.
Nephrosant's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Commercial Officer | Reveal Email/Phone |
Nephrosant Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Nephrosant?
Kidney transplantation is the treatment of choice for patients with end-stage kidney failure. However, the life of a kidney transplant is limited due to unrecognized immune injury. There is no sensitive, non-invasive method to detect this injury at an early-stage. We have developed a reliable, inexpensive, and noninvasive assay to monitor kidney injury.
keywords:Biotechnology, Healthcare, Diagnostics, Medical Technologies
$16M
Total Funding
13
Number of Employees
$1M
Revenue (est)
-62%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Nephrosant News
2022-03-22 - NephroSant Launches Two-Year Study of 2,000 Kidney ...
NephroSant is dedicated to all aspects of kidney health. The company was founded by Dr. Minnie Sarwal, a physician with deep scientific insight...
Other Companies in Brisbane
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.2M | 14 | -12% | N/A |
#2 | $1.2M | 14 | 17% | N/A |
#3 | $1.3M | 15 | -21% | N/A |
#4 | $1.3M | 15 | N/A | N/A |
#5 | $1.3M | 15 | -12% | N/A |